Rutherford, Sarah

Publications

Sort by

Co-Author Network

selected publications

MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. Blood advances. 2026 Academic Article GET IT
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma. Blood advances. 2026 Academic Article GET IT
Classic Hodgkin Lymphoma in the Older Adult: What's New?. Hematology/oncology clinics of North America. 2026 Review GET IT
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026 Academic Article GET IT
ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma. Transplantation and cellular therapy. 2025 Guideline GET IT
Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms?. Hematology. American Society of Hematology. Education Program. 2025 Review GET IT
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure. HemaSphere. 2025 Letter GET IT
The future of follicular lymphoma management: strategies on the horizon. Blood. 2025 Review GET IT
Prognostic discussions in patients with advanced lymphoma: Characteristics and challenges. Palliative & supportive care. 2025 Academic Article GET IT
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025 Academic Article GET IT
Times cited: 17
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. The New England journal of medicine. 2024 Academic Article GET IT
Times cited: 162
The Management of older patients with Hodgkin lymphoma: implications of S1826. Seminars in hematology. 2024 Review GET IT
Times cited: 1
Impact of imaging frequency on progression-free survival in Alliance trials enrolling patients with follicular lymphoma. Blood advances. 2024 Academic Article GET IT
Times cited: 2
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells. Cancer research. 2024 Academic Article GET IT
Times cited: 21
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023 Academic Article GET IT
Times cited: 43
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 Academic Article GET IT
Times cited: 61
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 16
Unmet mental health needs in patients with advanced B-cell lymphomas. Palliative & supportive care. 2022 Academic Article GET IT
Times cited: 8
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clinical lymphoma, myeloma & leukemia. 2021 Academic Article GET IT
Times cited: 7
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood advances. 2021 Academic Article GET IT
Times cited: 30
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. The Lancet. Haematology. 2021 Academic Article GET IT
Times cited: 24
Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 1
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 1
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. Blood advances. 2020 Academic Article GET IT
Times cited: 19
Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma. Journal of palliative medicine. 2019 Academic Article GET IT
Times cited: 10
Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. Leukemia & lymphoma. 2019 Letter GET IT
Times cited: 2
Surveillance scanning in lymphoma. Clinical advances in hematology & oncology : H&O. 2019 Review GET IT
Times cited: 2
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 11
PET beyond Deauville in diffuse large B-cell lymphoma. Leukemia & lymphoma. 2019 Comment GET IT
DLBCL Cell of Origin: What Role Should It Play in Care Today?. Oncology (Williston Park, N.Y.). 2018 Review GET IT
Times cited: 11
Management of Relapsed and Refractory Hodgkin Lymphoma in 2018. JAMA oncology. 2018 Academic Article GET IT
Times cited: 1
Extracellular vesicles in DLBCL provide abundant clues to aberrant transcriptional programming and genomic alterations. Blood. 2018 Academic Article GET IT
Times cited: 31
Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee. British journal of haematology. 2018 Letter GET IT
Lymphoma "benchmark" or "bench-smudge"?. Blood. 2017 Comment GET IT
Times cited: 2
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials. British journal of haematology. 2017 Academic Article GET IT
Times cited: 11
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 4
The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval. Oncology (Williston Park, N.Y.). 2017 Editorial Article GET IT
Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. Cell cycle (Georgetown, Tex.). 2016 Academic Article GET IT
Times cited: 8
Management strategies in patients with diffuse large B-cell lymphoma and severe haemophilia. Haemophilia : the official journal of the World Federation of Hemophilia. 2015 Letter GET IT
Times cited: 1
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 29
Splenic lymphomas: is there still a role for splenectomy?. Oncology (Williston Park, N.Y.). 2012 Comment GET IT
Times cited: 1
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 15
Hyperlipemia and oxidation of LDL induce vascular smooth muscle cell growth: an effect mediated by the HLH factor Id3. Journal of vascular research. 2005 Academic Article GET IT
Times cited: 24

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Preemptive Rituximab for the Prevention of PTLD in EBV-Positive Solid Organ Transplant Recipients awarded by Lymphoma Research Foundation Co-Principal Investigator 2025 - 2027

more ...

less ...

Background

education and training

M.D., University of Virginia School of Medicine 2009
B.A., University of Virginia 2003

Contact

full name

Sarah Rutherford

primary email

sar2014@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Sarah Rutherford Associate Professor of Clinical Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage